Jim Cramer was absolutely ecstatic over the results of Alphabet, Amazon and Microsoft on Thursday. It was clear to him that these three companies have figured out the most important trends — social, mobile, cloud, analytics and the Internet of things — and are running away from the pack with them.
"What the heck, let me just spell it out for you: Alphabet, Amazon and Microsoft all delivered phantasmagorical quarters last night, legendary, epic, almost mythological in their awesomeness. Just some of the best numbers we have seen in ages," Cramer said.
As a result, all three stocks skyrocketed Friday. All of the investors who bet against these three titans were left crying by the end of the day.
What does that mean for everyone else?
Cramer recommended letting the short sellers finish their buying before pulling the trigger on these stocks. Once the short squeeze is over, there will still be plenty left to go around.
After a tremendous earnings week like this one, Cramer found it hard to believe that it can be topped. This earnings season has turned everything on its head in a vicious stock rotation that includes buying the big industrial and tech names and, up until Friday, throwing away health care stocks.
"But that does not mean my rolling bear market within a bull market thesis has gone away," the "Mad Money" host said.
Health care might have escaped from the bear on Friday, but retail was mauled. So, where should investors go from here? Cramer outlined his game plan of events and stocks to watch, to help investors find the way.
Apple: Though the stock still remains cheaper than most other technology stocks that exploded higher on Friday, Apple can still get hurt. Cramer has noticed that Apple's stock has been creeping up in anticipation of the quarter, so he will be on alert for any bruising, since the tech bar is set so high.
It was also three little words from VF Corp and a small guide down, and the entire retail sector plummeted in one day.
So, when worldwide apparel company VF Corp said that a broad slowdown would take revenue growth to 8 percent from 10 percent, retail investors jumped ship from the whole group. They didn't bother to find out what stores were actually being impacted or if VF Corp's issue extended to other companies.
At this point Cramer would not be surprised if at least one of the big-time analysts who follow retail will downgrade the whole group.
"You need to get ahead of that negative commentary, hence why so many retail stocks got hurt yesterday," Cramer said. (Tweet this)
Cramer was left scratching his head in confusion when Skechers stock plunged dramatically on Friday.
The footwear company was considered among the hottest of the hot stocks, up more than 150 percent for the year, going into the quarter. Wall Street had gotten used to Skechers knocking it out of the park each time it reported earnings, so when the numbers were viewed by many as being disappointing, the stock lost 31 percent in a single session.
"Did Skechers truly blow it, or is the market overreacting because the expectations had simply gotten too high?" the "Mad Money" host asked.
Most important of all, Skechers maintained its guidance for the next quarter. Could this be a rare buying opportunity for the stock? To find out, Cramer spoke with the Skechers chief operating officer and chief financial officer, David Weinberg.
He said that he thinks this was an overreaction, stating, "Business is very good and continues to be very good."
Despite the rebound in biotechs on Friday, the group has taken a serious beating recently. However, when Cramer sees a privately held biotech that is doing exciting work, he wants to bring it to investors' attention before its approach spills over into the public market.
Intarcia Therapeutics is a privately held biotech that has developed a disruptive technology to treat Type 2 diabetes. One of the problems with diabetes drugs is that they need to be injected, and many patients do not take them regularly, if at all.
Intarcia has developed a two-inch rod that is implanted under the patient's skin and delivers a steady dose of Extenatide, a major Type 2 diabetes drug, over the course of an entire year as opposed to getting injections once a week.
The company announced positive Phase 3 trial results on its lead product back in August, and it acquired Phoundry Pharmaceuticals last month.
To learn more about the game-changing way that it treats diabetes, Cramer spoke to Intarcia Therapeutics Chairman and CEO Kurt Graves.
"Now that we have got this platform really figured out, what we are doing is we are building a pipeline of once a year medicines in big chronic diseases," Graves said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Amsurg Corp: "I'm staying away from the health care stocks in that cohort right now. Let's just let them come in. There's a lot of short sellers, we've got to wait."
McCormick & Co: "I've been recommending McCormick since the show began. I think that the stock remains a great buy."